Loading...
•
Mar 31, 2024
Nektar Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
Nektar Therapeutics reported first quarter 2024 financial results with revenue of $21.6 million and a net loss of $36.8 million, or $0.19 loss per share. Cash and investments were $326.0 million at the end of the quarter, expected to support operations into the third quarter of 2026. The company is advancing its immunology and inflammation pipeline, with Phase 2b studies for REZPEG on track.
Cash and investments in marketable securities were $326.0 million as of March 31, 2024.
Revenue for the first quarter of 2024 was $21.6 million, consistent with the first quarter of 2023.
Net loss for the first quarter of 2024 was $36.8 million, or $0.19 loss per share.
Advancing REZPEG in Phase 2b studies for atopic dermatitis and alopecia areata, with topline data expected in the first half of 2025.
Forward Guidance
Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...